CDX2 and neoplasm: Furthermore, several cancer-critical genes had high-level amplifications in one tumor each in the inhouse dataset and among these, amplifications of CDX2 were particularly prevalent in the TCGA cohort, with a 1.6% prevalence of focal high-level amplifications and a prevalence of 4.7% when also including low-level amplifications.